Cargando…
The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways
The classical BCR-ABL-negative Myeloproliferative Neoplasms (MPN) are a group of heterogeneous haematological diseases characterized by constitutive JAK-STAT pathway activation. Targeted therapy with Ruxolitinib, a JAK1/2-specific inhibitor, achieves symptomatic improvement but does not eliminate th...
Autores principales: | Cardoso, Bruno A., Belo, Hélio, Barata, João T., Almeida, António M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666616/ https://www.ncbi.nlm.nih.gov/pubmed/26623653 http://dx.doi.org/10.1371/journal.pone.0143897 |
Ejemplares similares
-
Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms
por: Silva, Gabriela, et al.
Publicado: (2013) -
Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014) -
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases
por: Civallero, Monica, et al.
Publicado: (2017) -
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015) -
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)